Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | STE/STE20/YSK protein kinase | 0.0205 | 0.2921 | 0.2636 |
Trichomonas vaginalis | STE family protein kinase | 0.0205 | 0.2921 | 1 |
Trypanosoma brucei | STE20-like serine/threonine-protein kinase 1, putative | 0.0105 | 0 | 0.5 |
Plasmodium vivax | serine/threonine-specific protein kinase, putative | 0.0205 | 0.2921 | 0.5 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.0166 | 0.1776 | 0.1445 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0105 | 0 | 0.5 |
Loa Loa (eye worm) | STE/STE20/MST protein kinase | 0.0446 | 1 | 1 |
Echinococcus granulosus | serine:threonine protein kinase 3 | 0.0446 | 1 | 1 |
Leishmania major | protein kinase, putative | 0.0105 | 0 | 0.5 |
Giardia lamblia | Kinase, STE STE20 | 0.0105 | 0 | 0.5 |
Echinococcus multilocularis | serine threonine protein kinase | 0.0205 | 0.2921 | 0.2921 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0205 | 0.2921 | 0.2193 |
Plasmodium falciparum | protein kinase, putative | 0.0205 | 0.2921 | 0.5 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0105 | 0 | 0.5 |
Echinococcus granulosus | serine threonine protein kinase | 0.0205 | 0.2921 | 0.2618 |
Trichomonas vaginalis | STE family protein kinase | 0.0205 | 0.2921 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase 3 | 0.0446 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0205 | 0.2921 | 1 |
Echinococcus multilocularis | leucine rich repeat serine:threonine protein | 0.0118 | 0.0387 | 0.0387 |
Brugia malayi | Protein kinase domain containing protein | 0.0166 | 0.1776 | 0.1445 |
Schistosoma mansoni | ste20-related kinase | 0.0344 | 0.6997 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.